Anti-VEGF administration is currently the most commonly used treatment option for wet age-related macular degeneration (AMD), macular edema secondary to retinal vein occlusion (RVO), and diabetic macular edema (DME) [18–20]. This evidence concerns the gene VEGFA and age-related macular degeneration.